Trials & Filings

GSK’s Asthma Drug Wins FDA Approval

Nucala shown to reduce frequency of severe asthma attacks

GlaxoSmithKline’s Nucala (Mepolizumab) therapy has been approved by the FDA to treat severe asthma attacks in combination with other drugs. Nucala is an injection administered once every four weeks that is approved as an add-on maintenance treatment for patients aged 12 and older.
 
In trials, patients who received Nucala had fewer asthma attacks that required hospitalization or emergency-room visits and reported longer breaks between asthma attacks.
 
The most common reported side effects included redness, swelling and itching in the injection area, back pain and fatigue.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters